Clinical Trial Update: Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

View source ↗

Summary

A clinical trial is evaluating tislelizumab plus chemotherapy as conversion therapy for unresectable locally advanced esophageal squamous cell carcinoma. Recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shandong Provincial Hospital | Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma | Status: RECRUITING